S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

United Therapeutics Stock Forecast, Price & News

-6.54 (-3.27%)
(As of 11/26/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
227,942 shs
Average Volume
362,566 shs
Market Capitalization
$8.72 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive UTHR News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

United Therapeutics logo

About United Therapeutics

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It also involves in the research and development of new indications and delivery devices for its product and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$1.48 billion
Cash Flow
$12.25 per share
Book Value
$85.04 per share


Net Income
$514.80 million
Pretax Margin




Free Float
Market Cap
$8.72 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Social Links


Overall MarketRank

2.47 out of 5 stars

Medical Sector

135th out of 1,391 stocks

Pharmaceutical Preparations Industry

57th out of 669 stocks

Analyst Opinion: 2.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 2.5 5 -4 -3 -2 -1 -

United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions

Is United Therapeutics a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" United Therapeutics stock.
View analyst ratings for United Therapeutics
or view top-rated stocks.

How has United Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

United Therapeutics' stock was trading at $93.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, UTHR stock has increased by 106.0% and is now trading at $193.64.
View which stocks have been most impacted by COVID-19

Are investors shorting United Therapeutics?

United Therapeutics saw a drop in short interest in November. As of November 15th, there was short interest totaling 1,880,000 shares, a drop of 21.3% from the October 31st total of 2,390,000 shares. Based on an average trading volume of 368,100 shares, the short-interest ratio is currently 5.1 days. Currently, 4.3% of the shares of the company are sold short.
View United Therapeutics' Short Interest

When is United Therapeutics' next earnings date?

United Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for United Therapeutics

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) posted its earnings results on Wednesday, November, 3rd. The biotechnology company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.37 by $0.05. The biotechnology company earned $444.70 million during the quarter, compared to the consensus estimate of $421.45 million. United Therapeutics had a trailing twelve-month return on equity of 12.93% and a net margin of 27.94%. The firm's quarterly revenue was up 17.0% compared to the same quarter last year. During the same period in the previous year, the company earned $3.84 earnings per share.
View United Therapeutics' earnings history

What price target have analysts set for UTHR?

8 Wall Street analysts have issued 12 month price targets for United Therapeutics' shares. Their forecasts range from $196.00 to $275.00. On average, they anticipate United Therapeutics' share price to reach $224.38 in the next year. This suggests a possible upside of 15.9% from the stock's current price.
View analysts' price targets for United Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are United Therapeutics' key executives?

United Therapeutics' management team includes the following people:
  • Martine A. Rothblatt, Chairman & Chief Executive Officer
  • Michael Ian Benkowitz, President & Chief Operating Officer
  • James Christopher Edgemond, Chief Financial Officer & Treasurer
  • Paul A. Mahon, Secretary, Executive VP & General Counsel
  • Dewey Steadman, Head-Investor Relations

What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO?

64 employees have rated United Therapeutics CEO Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among United Therapeutics' employees.

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), (CELG), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.56%), Renaissance Technologies LLC (6.72%), Bank of New York Mellon Corp (1.88%), Deutsche Bank AG (1.88%), Fuller & Thaler Asset Management Inc. (1.56%) and Geode Capital Management LLC (1.55%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Paul A Mahon, Paul A Mahon, Raymond Dwek, Richard Giltner and Tommy G Thompson.
View institutional ownership trends for United Therapeutics

Which major investors are selling United Therapeutics stock?

UTHR stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Assenagon Asset Management S.A., Invesco Ltd., Thompson Siegel & Walmsley LLC, Great Point Partners LLC, Martingale Asset Management L P, Renaissance Technologies LLC, and Brahman Capital Corp.. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Paul A Mahon, and Raymond Dwek.
View insider buying and selling activity for United Therapeutics
or view top insider-selling stocks.

Which major investors are buying United Therapeutics stock?

UTHR stock was purchased by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Epoch Investment Partners Inc., Two Sigma Advisers LP, Bank of Nova Scotia, Two Sigma Investments LP, Bank of New York Mellon Corp, Arrowstreet Capital Limited Partnership, and Goldman Sachs Group Inc..
View insider buying and selling activity for United Therapeutics
or or view top insider-buying stocks.

How do I buy shares of United Therapeutics?

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $193.64.

How much money does United Therapeutics make?

United Therapeutics has a market capitalization of $8.72 billion and generates $1.48 billion in revenue each year. The biotechnology company earns $514.80 million in net income (profit) each year or $9.87 on an earnings per share basis.

How many employees does United Therapeutics have?

United Therapeutics employs 950 workers across the globe.

When was United Therapeutics founded?

United Therapeutics was founded in 1996.

What is United Therapeutics' official website?

The official website for United Therapeutics is www.unither.com.

Where are United Therapeutics' headquarters?

United Therapeutics is headquartered at 1040 SPRING ST, SILVER SPRING MD, 20910.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at (301) 608-9292, via email at [email protected], or via fax at 301-608-9291.

This page was last updated on 11/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.